Prothena Co. plc (NASDAQ:PRTA – Get Rating) CFO Tran Nguyen sold 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 19th. The stock was sold at an average price of $56.44, for a total transaction of $564,400.00. Following the completion of the transaction, the chief financial officer now directly owns 3,200 shares in the company, valued at $180,608. The transaction was disclosed in a document filed with the SEC, which is available through this link.
Tran Nguyen also recently made the following trade(s):
- On Wednesday, September 21st, Tran Nguyen sold 10,000 shares of Prothena stock. The stock was sold at an average price of $30.75, for a total transaction of $307,500.00.
- On Wednesday, August 24th, Tran Nguyen sold 10,000 shares of Prothena stock. The stock was sold at an average price of $30.17, for a total transaction of $301,700.00.
Prothena Price Performance
PRTA stock traded up $2.16 during midday trading on Friday, hitting $58.22. The stock had a trading volume of 489,396 shares, compared to its average volume of 519,090. Prothena Co. plc has a 52-week low of $21.06 and a 52-week high of $64.00. The firm has a market cap of $2.73 billion, a price-to-earnings ratio of -242.58 and a beta of 0.49. The business has a 50-day moving average of $38.87 and a two-hundred day moving average of $32.86.
Prothena (NASDAQ:PRTA – Get Rating) last issued its quarterly earnings results on Monday, August 8th. The biotechnology company reported ($0.88) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.37). Prothena had a negative return on equity of 0.33% and a negative net margin of 1.03%. The company had revenue of $1.31 million during the quarter, compared to analysts’ expectations of $20.12 million. Research analysts predict that Prothena Co. plc will post -2.57 earnings per share for the current year.
Wall Street Analysts Forecast Growth
A number of equities research analysts recently weighed in on PRTA shares. Royal Bank of Canada raised their price target on shares of Prothena from $45.00 to $52.00 in a report on Wednesday, September 28th. StockNews.com started coverage on shares of Prothena in a report on Wednesday, October 12th. They set a “hold” rating for the company. Oppenheimer boosted their price objective on shares of Prothena from $100.00 to $110.00 and gave the stock an “outperform” rating in a research note on Thursday, September 29th. JMP Securities boosted their price target on shares of Prothena from $50.00 to $81.00 in a report on Wednesday, September 28th. Finally, Bank of America upgraded shares of Prothena from a “neutral” rating to a “buy” rating and upped their target price for the company from $45.00 to $65.00 in a research report on Wednesday, September 28th. One research analyst has rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, Prothena currently has a consensus rating of “Moderate Buy” and a consensus price target of $76.20.
Hedge Funds Weigh In On Prothena
Several institutional investors and hedge funds have recently modified their holdings of the stock. AlphaCrest Capital Management LLC purchased a new stake in shares of Prothena in the first quarter valued at approximately $561,000. Capital Fund Management S.A. raised its stake in shares of Prothena by 131.2% in the first quarter. Capital Fund Management S.A. now owns 120,393 shares of the biotechnology company’s stock valued at $4,403,000 after acquiring an additional 68,330 shares in the last quarter. Virginia Retirement Systems ET AL increased its holdings in Prothena by 78.7% in the first quarter. Virginia Retirement Systems ET AL now owns 13,400 shares of the biotechnology company’s stock valued at $490,000 after buying an additional 5,900 shares during the last quarter. Rock Springs Capital Management LP increased its holdings in Prothena by 2.4% in the first quarter. Rock Springs Capital Management LP now owns 663,530 shares of the biotechnology company’s stock valued at $24,265,000 after buying an additional 15,800 shares during the last quarter. Finally, Paradigm Biocapital Advisors LP purchased a new position in Prothena in the first quarter valued at $9,799,000. Institutional investors and hedge funds own 93.92% of the company’s stock.
Prothena Company Profile
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson’s disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer’s disease.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Prothena, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Prothena wasn’t on the list.
While Prothena currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Read More: Prothena Co. plc (NASDAQ:PRTA) CFO Tran Nguyen Sells 10,000 Shares